Valneva SE Sponsored ADR (NASDAQ:VALN) Short Interest Update

Key Points

• Valneva SE experienced an 81.3% decrease in short interest during August, with total short interest dropping to 14,000 shares as of August 31st.
• The company reported a loss of $0.16 per share for the quarter ending August 12th, which exceeded analysts’ expectations, alongside revenues of $54.84 million.
• Several research firms have set a consensus rating of "Buy" for Valneva, with an average price target of $15.00

Valneva SE Sponsored ADR (NASDAQ:VALN - Get Free Report) was the recipient of a large decline in short interest in August. As of August 31st, there was short interest totaling 14,000 shares, a decline of 81.3% from the August 15th total of 74,900 shares. Based on an average daily volume of 71,700 shares, the days-to-cover ratio is currently 0.2 days. Currently, 0.0% of the company's stock are sold short. Currently, 0.0% of the company's stock are sold short. Based on an average daily volume of 71,700 shares, the days-to-cover ratio is currently 0.2 days.

Hedge Funds Weigh In On Valneva

Large investors have recently modified their holdings of the business. Marex Group plc purchased a new position in shares of Valneva during the 2nd quarter worth approximately $64,000. GAMMA Investing LLC purchased a new position in shares of Valneva during the 1st quarter worth approximately $94,000. Finally, Frazier Life Sciences Management L.P. purchased a new position in shares of Valneva during the 2nd quarter worth approximately $8,240,000. 11.39% of the stock is owned by hedge funds and other institutional investors.

Valneva Stock Performance

NASDAQ VALN traded down $0.09 on Tuesday, hitting $8.85. 19,962 shares of the company's stock were exchanged, compared to its average volume of 70,128. The firm has a market cap of $760.05 million, a price-to-earnings ratio of -9.03 and a beta of 1.78. The firm's 50-day moving average price is $8.42 and its two-hundred day moving average price is $7.14. Valneva has a fifty-two week low of $3.62 and a fifty-two week high of $12.25. The company has a debt-to-equity ratio of 0.66, a current ratio of 2.27 and a quick ratio of 1.77.

Valneva (NASDAQ:VALN - Get Free Report) last issued its earnings results on Tuesday, August 12th. The company reported ($0.16) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.27) by $0.11. The business had revenue of $54.84 million during the quarter, compared to the consensus estimate of $46.28 million. Valneva had a negative return on equity of 34.78% and a negative net margin of 33.87%. On average, research analysts expect that Valneva will post 0.13 EPS for the current year.

Analyst Ratings Changes

A number of analysts have issued reports on VALN shares. HC Wainwright reaffirmed a "buy" rating and set a $18.00 price target on shares of Valneva in a report on Monday, August 25th. Wall Street Zen raised Valneva to a "hold" rating in a report on Saturday, September 6th. Jefferies Financial Group set a $14.00 price target on Valneva and gave the stock a "buy" rating in a report on Monday, August 25th. Finally, Guggenheim decreased their price target on Valneva from $14.00 to $13.00 and set a "buy" rating for the company in a report on Monday, September 8th. Three investment analysts have rated the stock with a Buy rating, According to MarketBeat, the stock presently has an average rating of "Buy" and a consensus price target of $15.00.

Valneva Company Profile

Valneva SE, a specialty vaccine company, develops, manufactures, and commercializes prophylactic vaccines for infectious diseases with unmet needs. It offers IXIARO, an inactivated Vero cell culture-derived Japanese encephalitis vaccine indicated for active immunization against Japanese encephalitis; DUKORAL, an oral vaccine for the prevention of diarrhea caused by Vibrio cholera and/or heat-labile toxin producing enterotoxigenic Escherichia coli bacterium; IXCHIQ, a single-dose, live-attenuated vaccine for the prevention of disease caused by chikungunya virus; and VLA2001, an inactivated whole-virus COVID-19 vaccine.